The US company has relinquished its right to a 180-day exclusivity period for the drug.
Andrx Corporation (Nasdaq:ADRX) announced on Friday that that it had relinquished its right to a 180-day period of marketing exclusivity for the 150mg strength of nicotine addiction treatment Zyban (bupropion), and that it would share its profits on the drug with Teva (Nasdaq:TEVA).
The announcement followed approval by the US Food and Drug Administration of an ANDA (abbreviated new drug application) for the drug by Teva's strategic partner Impax Corporation (IPXL).
Zyban, the ethical version of bupropion is produced by GlaxoSmithKline PLC (GSK), and has annual sales amounting to $130 million. The treatment has recently been the subject of an extensive marketing campaign in Israel.
In August last year, Teva announced that it had signed a marketing deal with Andrx and Impax for GlaxoSmithKline's Wellbutrin and Zyban.
Published by Globes [online] - www.globes.co.il - on May 30, 2004